Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer pet parasiticide receives new FDA, EMA indications

Bayer pet parasiticide receives new FDA, EMA indications

27th December 2013

Bayer Animal Health has announced it has received further indications for Advocate/Advantage Multi – a spot-on parasiticide for dogs and cats – in the US and Europe.

In the US, the Food and Drug Administration (FDA) has approved the product as a treatment for circulating microfilaria – the first larval stage of heartworm – in dogs, as well as for sarcoptic mange.

Meanwhile, Advantage Multi for cats has also become the first product to win FDA approval for treating adult flea infestations and prevent heartworm in ferrets.

In Europe, Advocate has been awarded new indications in all pets for the prevention of the Spriocerca lupi oesophageal worm and the Dirofilaria repens skinworm, and to treat and reduce microfilariae of the D. immitis and D. repens heartworms respectively.

Commenting on the new indications, Georg von Samson-Himmelstjerna, director of the Institute for Parasitology and Tropical Veterinary Medicine, said: "Topical parasiticides are well established as invaluable treatments and the broader the protection offered the better."ADNFCR-8000103-ID-801676405-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.